Investment case
Regeneron Pharmaceuticals, Inc.
REGN · 18 developments mapped · last assessed 2026-09-28
Market Ontology has mapped 18 macro, policy, and market developments to Regeneron Pharmaceuticals, Inc. since 2026-09-06. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Valuation
No validated run has been published for REGN yet, so no modelled value is shown. The REGN valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run REGN on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
Current case
- Strongest support
Atopic dermatitis therapeutic market projected to reach $33.42B by 2035 on biologics
Direct increase in market opportunity for Dupixent (co-developed with Sanofi), a leading biologic in atopic dermatitis. Increased sales volume and potential for price stability/growth.
· Moves revenue growth rate, market share assumptions, terminal growth rate
- Main threat
Vertex Inaxaplin Phase IIb Cuts Proteinuria in Kidney Disease Trial
Increased competitive pressure in the kidney disease therapeutic area, potentially impacting future market share for existing or pipeline drugs.
· Moves market share projections for kidney disease therapies, pricing power for competing drugs
- Open question
Moderna and Merck Report Positive Phase III Trial Results for mRNA Cancer Therapy
Increased competition in the oncology market, particularly for melanoma, but also potential for broader validation of novel therapeutic approaches.
· Moves competitive landscape in oncology, peak sales estimates for existing oncology products
What changed, by assumption
- 2026-09-06Atopic dermatitis therapeutic market projected to reach $33.42B by 2035 on biologics
- 2026-09-06Atopic Dermatitis Market Projected to Reach $33.4B by 2035 at 7.7% CAGR
- 2026-09-06Atopic Dermatitis Market Projected to Reach $33.42B by 2035 on Biologics Demand
- 2026-09-06Atopic Dermatitis Biopharma Market Projected to Reach $33.4B by 2035 at 7.7% CAGR
- 2026-09-06Atopic Dermatitis Market Projected to Reach $33.4B by 2035 on Biologics Expansion
- 2026-09-06Atopic Dermatitis Market Projected to Reach $33.4B by 2035 on Biologics Growth
- 2026-09-16Moderna and Merck Report Positive Phase III Trial Results for mRNA Cancer Therapy
- 2026-09-27Hangzhou Global Open-Source AI Finals Conclude with 1M RMB Biotech Prize
Event impact log
Full ledger →| Date | Mechanism | Direction | Horizon | Impact |
|---|---|---|---|---|
| 2026-09-28 | Eli Lilly Discontinues Sub-Efficacy GLP-1 Drug Amid Pipeline R&D Reallocation | watch | 3-12m | 0.20 |
| 2026-09-28 | Eli Lilly drops pipeline GLP-1 candidate on efficacy while maintaining franchise lead | mixed | 3-12m | 0.20 |
| 2026-09-28 | Eli Lilly Discontinues Early-Stage GLP-1 Candidate Following Efficacy Review | Bullish | 1-3m | 0.10 |
| 2026-09-28 | Eli Lilly Drops Experimental GLP-1 Candidate as Core Incretin Portfolio Reaches 65% of Sales | Bullish | 3-12m | 0.20 |
| 2026-09-27 | Eli Lilly Drops Experimental Obesity Candidate While Core GLP-1s Exceed 65% of Revenue | watch | 3-12m | 0.20 |
| 2026-09-27 | Hangzhou Global Open-Source AI Finals Conclude with 1M RMB Biotech Prize | Bullish | 1-5y | 0.30 |
| 2026-09-24 | Vertex Inaxaplin Phase IIb Cuts Proteinuria in Kidney Disease Trial | Bearish | 3-12m | 0.30 |
| 2026-09-24 | Vertex reports positive Phase IIb inaxaplin results for kidney disease | watch | 1-5y | 0.30 |
| 2026-09-24 | Vertex Reports Phase IIb Data for Inaxaplin with 42.7% Proteinuria Drop in AMKD | watch | 3-12m | 0.25 |
| 2026-09-24 | Vertex Reports Positive Phase IIb Kidney Disease Data for Inaxaplin | watch | 3-12m | 0.30 |
| 2026-09-17 | Telomir Pharmaceuticals Announces Peer-Reviewed Publication of Telomir-Zn Preclinical Research in AMD | watch | 1-5y | 0.10 |
| 2026-09-16 | Moderna and Merck Report Positive Phase III Trial Results for mRNA Cancer Therapy | mixed | 3-12m | 0.40 |